Skip to main content

Table 4 Comparison of serum AST, ALT, CREA, TBIL, ALB and BUN levels between the two patient groups

From: A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

 

Combination Group

Monotherapy Group

Z

P

AST(U/L)

23.0 (20.0, 30.0)

25.0 (19.0, 35.5)

-0.49

0.63

ALT(U/L)

20.5 (15.0, 29.0)

23.0 (16.0, 37.5)

-1.09

0.27

CREA(μmoI/L)

58.6 (52.5, 78.9)

64.9 (51.0, 75.0)

-0.26

0.79

TBIL(μmoI/L)

10.5 (9.3, 15.6)

13.4 (9.8, 16.2)

-1.11

0.27

ALB(g/L)

41.2 (38.6, 43.9)

41.5 (39.6, 44.4)

-0.55

0.58

BUN(mmoI/L)

4.8 (3.9, 6.5)

4.7 (3.8, 5.2)

-0.92

0.36

  1. Data are mean median (IQR)